Overview

" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD "

Status:
Not yet recruiting

Trial end date:
2024-03-29

Target enrollment:

Participant gender:

Summary

The treatment of adult patients with congenital heart disease (ACHD) and heart failure (HF) represents a great challenge since, to date, there is no standardized guideline for this specific population. Although new treatments for HF have been proposed, such as Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors and neprilisin and angiotensin receptor inhibitors, the benefit of these drugs in patients with HF associated with congenital heart disease in adults has not yet been demonstrated. For this reason, this study pretends to evaluate the efficacy of empagliflozin and sacubitril/valsartan in this population.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Instituto Nacional de Cardiologia Ignacio Chavez

Collaborator:

Boehringer Ingelheim laboratory

Treatments:

Empagliflozin
Sacubitril and valsartan sodium hydrate drug combination
Valsartan